Management of MS-relapse during alemtuzumab therapy: Is it really B-cell-mediated?

Mult Scler Relat Disord. 2018 Jan:19:6-7. doi: 10.1016/j.msard.2017.10.014. Epub 2017 Oct 22.

Authors

Philipp Schwenkenbecher¹, Julian Deppe¹, Martin W Hümmert¹, Roland Jacobs², Paul Bronzlik³, Martin Stangel¹, Thomas Skripuletz⁴

Affiliations

¹ Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.
² Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany.
³ Institute for Neuroradiology, Hannover Medical School, Hannover, Germany.
⁴ Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany. Electronic address: [email protected].

PMID: 29158120
DOI: 10.1016/j.msard.2017.10.014

No abstract available

Publication types

Editorial